EQUITY RESEARCH MEMO
DNA Compass
Generated 5/9/2026
Executive Summary
Conviction (model self-assessment)65/100
DNA Compass is a San Francisco-based company founded in 2018 that leverages advanced genome mapping technology to connect individuals at specific genomic locations, facilitating collaboration between patient advocacy groups and researchers. By integrating local data infrastructure, the platform aims to improve access and cooperation across global genomic datasets, ultimately accelerating research and discovery. Though still operating in stealth with no disclosed funding or stage details, DNA Compass addresses a critical need for data interoperability in genomics, positioning itself as a potential enabler for global research initiatives.
Upcoming Catalysts (preview)
- TBDStrategic partnership with a major patient advocacy group70% success
- Q3 2026Integration with a global genomic database (e.g., GA4GH) or launch of a beta platform60% success
- Q4 2026Series A funding announcement to scale platform development55% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)